Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Operations (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Cash from Operations for 14 consecutive years, with 3115835.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 1597.64% year-over-year to 3115835.0, compared with a TTM value of 6161156.0 through Dec 2025, up 11.91%, and an annual FY2025 reading of 2837272.0, up 74.23% over the prior year.
  • Cash from Operations was 3115835.0 for Q4 2025 at Neuroone Medical Technologies, down from 1525672.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1017817.0 in Q3 2022 and bottomed at 3809391.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 2203497.45, with a median of 2508247.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 150.16% in 2022, then tumbled 1597.64% in 2025.
  • Year by year, Cash from Operations stood at 2679136.0 in 2021, then tumbled by 30.35% to 3492253.0 in 2022, then dropped by 9.08% to 3809391.0 in 2023, then skyrocketed by 105.46% to 208049.0 in 2024, then tumbled by 1597.64% to 3115835.0 in 2025.
  • Business Quant data shows Cash from Operations for NMTC at 3115835.0 in Q4 2025, 1525672.0 in Q3 2025, and 1463505.0 in Q2 2025.